| abstract |
Isoquinoline compounds are disclosed for the treatment of various diseases and pathologies. More specifically, the present disclosure relates to the use of an isoquinoline compound, or analogs thereof, in the treatment of disorders characterized by activation of Wnt pathway signaling (eg, cancer, abnormal cell proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, autoimmune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions / disorders / diseases related to DYRK1A overexpression. |